论文信息 - The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis - 字舞流文

The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis

Y. Fragoso | M. Macías-Islas | A. Carrá | M. Boggild | W. Arruda | E. Comini-Frota | M. Ferreira | P. D. Gama | S. Gomes | D. Kaimen-Maciel | R. R. Morales | S. Georgetto | J. Lopes | F. Malfetano | A. Gallina | C. Vasconcelos | R. Alvarenga | P. Santoro | M. Gonçalves | A. Grzesiuk | A. Finkelsztejn | S. B. Ribeiro | P. Soares | M. Alvarenga | Juliana Finkelsztejn | M. C. Giacomo | H. Salminen | C. Patroclo | A. Tarulla | N. M. Morales | C. L. S. Oliveira | S. Alves‐Leon | Adriana Aguayo | S. Almeida | T. A. G. J. Ribeiro | J. B. B. Brooks | P. Onaha | G. Lourenço | Kirsty Deborah Schaerer | Lucas Dias de Freitas | Marcos Seefeld

[1] C. Pozzilli,et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis , 2012, Multiple sclerosis.

[2] F. Barros,et al. Patterns of deliveries in a Brazilian birth cohort: almost universal cesarean sections for the better-off. , 2011, Revista de saude publica.

[3] A. Finkelsztejn,et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta‐analysis of the literature , 2011, BJOG : an international journal of obstetrics and gynaecology.

[4] R. Gold,et al. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment , 2011, Multiple sclerosis.

[5] J. Skurnick,et al. Clinical consequences of MRI activity in treated multiple sclerosis , 2011, Multiple sclerosis.

[6] M. Hutchinson. Safety first, efficacy second in disease modifying therapies , 2011, Multiple sclerosis.

[7] M. Sandberg‐Wollheim,et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy , 2011, Multiple sclerosis.

[8] C. Pozzilli,et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis , 2010, Neurology.

[9] M. Boggild,et al. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes , 2010, Journal of Neurology.

[10] A. Ferraro,et al. Exclusive breastfeeding in southern Brazil: prevalence and associated factors. , 2010, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

[11] T. Berger. Current therapeutic recommendations in multiple sclerosis , 2009, Journal of the Neurological Sciences.

[12] C. Weber-Schoendorfer,et al. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study , 2009, Multiple sclerosis.

[13] J. De Keyser,et al. Parity and secondary progression in multiple sclerosis , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[14] M. Zappia,et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? , 2008, Journal of Neurology.

[15] N. Ragni,et al. Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding , 2006, Expert review of neurotherapeutics.

[16] R. Meister,et al. Post-marketing surveillance system for drugs in pregnancy--15 years experience of ENTIS. , 2005, Reproductive toxicology.

[17] Friedhelm Nachreiner,et al. Health and psychosocial effects of flexible working hours. , 2004, Revista de saude publica.

[18] J. Clayton-Smith,et al. A note on Pierre Marie (1853–1940) , 2004, Journal of Neurology, Neurosurgery & Psychiatry.